Cetuximab Disappointment for Stage III Colon Cancer

Monoclonal antibody therapy targeting Epidermal growth factor receptor does not improve disease-free survival for stage III colon cancer patients. 

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.